Last year was a remarkable year for biotech companies going public. Not only did an unusually large number of biotech companies go public, but a significant number of early-stage biotech companies went public at premium valuations relative to their later-clinical stage peers.
Originally published in Xconomy - February 28, 2019.
Please see full publication below for more information.
